Biomarkers in Prostate Cancer – Current Clinical Utility and Future Perspectives

Current tendencies in the treatment course of prostate cancer patients increase the need for reliable biomarkers that help in decision-making in a challenging clinical setting. Within the last decade, several novel biomarkers have been introduced. In the following comprehensive review article, we focus on diagnostic (PHI ®, 4K score, SelectMDx®, ConfirmMDx®, PCA3, MiPS, ExosomeDX, mpMRI) and prognostic (OncotypeDX GPS®, Prolaris®, ProMark®, DNA-ploidy, Decipher®) biomarkers that are in widespread clinical use and are supported by evidence.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Tags: Review Source Type: research